Faculty

Institution

Unit

Venue

Hongya Chen, Pharm.D.

Cardiology Pharmacy Specialist

Oregon Health & Science University

Affiliations

Center Of Hypertrophic Cardiomyopathy

Hongya Chen, Pharm.d. is currently serving as a Center Of Hypertrophic Cardiomyopathy Cardiology Pharmacy Specialist at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Hongya Chen, Pharm.D.

Oregon Health & Science University

Cardiology Pharmacy Specialist

You can click a keyword to filter the displayed items

cardiology pharmacology medicine cardiovascular disease heart failure cardiovascular research cardiomyopathy cardiac pathologies hypertrophic cardiomyopathy critical care health policy cardiovascular interventions respiratory medicine cardiovascular function cardiovascular pharmacology cardiovascular toxicity structural heart disease cerebrovascular disease commercial tafamidis initial experience expensive cardiac medication congenital heart surgery neurology internal medicine cardiovascular imaging neuropathology nuclear cardiology myositis echocardiography circulatory physiology neurodegenerative diseases translational medicine

Notable Scholarly Works

Notable Federal Grants

Collaborators

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association (2025)

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy. Journal of the American Heart Association (2025)

Bryton J. DavisHailey VolkOlives NguyenDaniel KamnaHongya ChenRoberto Barriales‐VillaPablo Garcia‐PaviaIacopo OlivottoAnjali T. OwensCaroline J. CoatsTheodore P. AbrahamScott D. SolomonMartin S. MaronAhmad Masri

cardiovascular functionmedicinecardiovascular researchcardiologycardiac pathologiescardiomyopathyhypertrophic cardiomyopathycardiovascular diseaseheart failure

Medicare Spending on Tafamidis From 2019-2021 - Regional Disparities and Nationwide Trends. Journal of the American College of Cardiology (2024)

National and Regional Medicare Spending on Tafamidis, 2019-2021. JAMA Network Open (2024)

Efficacy and Safety of Dofetilide and Sotalol in Patients With Hypertrophic Cardiomyopathy. Communications Medicine (2023)

pharmacologystructural heart diseasemedicinecritical carecardiovascular researchcardiologycardiovascular toxicitycardiovascular pharmacologycardiac pathologiescardiovascular interventionscardiomyopathyhypertrophic cardiomyopathycardiovascular diseaseheart failure

Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer. Journal of the American Heart Association (2022)

Hongya ChenPranav ChandrashekarKatherine FischerDayna CarlsonUrja NarayanJack ChenAhmad Masri

pharmacologyhealth policymedicinerespiratory medicinecardiologycerebrovascular diseasecardiovascular disease

Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History. JAMA Cardiology (2020)

Ahmad MasriHongya ChenCatherine WongKatherine L. FischerChafic KaramWalid F. GelladStephen B. Heitner

expensive cardiac medicationpharmacologycardiologyinitial experiencecommercial tafamidis

1
10 / page

Hongya Chen, Pharm.D.

Cardiology Pharmacy Specialist

Oregon Health & Science University

Affiliations

Center Of Hypertrophic Cardiomyopathy

Hongya Chen, Pharm.d. is currently serving as a Center Of Hypertrophic Cardiomyopathy Cardiology Pharmacy Specialist at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Hongya Chen, Pharm.D.

Oregon Health & Science University

Cardiology Pharmacy Specialist

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association (2025)

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy. Journal of the American Heart Association (2025)

cardiovascular functionmedicinecardiovascular researchcardiologycardiac pathologiescardiomyopathyhypertrophic cardiomyopathycardiovascular diseaseheart failure

Medicare Spending on Tafamidis From 2019-2021 - Regional Disparities and Nationwide Trends. Journal of the American College of Cardiology (2024)

National and Regional Medicare Spending on Tafamidis, 2019-2021. JAMA Network Open (2024)

Efficacy and Safety of Dofetilide and Sotalol in Patients With Hypertrophic Cardiomyopathy. Communications Medicine (2023)

Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer. Journal of the American Heart Association (2022)

Hongya ChenPranav ChandrashekarKatherine FischerDayna CarlsonUrja NarayanJack ChenAhmad Masri

pharmacologyhealth policymedicinerespiratory medicinecardiologycerebrovascular diseasecardiovascular disease

Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History. JAMA Cardiology (2020)

Ahmad MasriHongya ChenCatherine WongKatherine L. FischerChafic KaramWalid F. GelladStephen B. Heitner

expensive cardiac medicationpharmacologycardiologyinitial experiencecommercial tafamidis

1
10 / page